VitaGraft

Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025

IRVINE, Calif., April 2, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. In addition, CEO Josh Riggs will participate in a fireside chat at the conference. During the event, Josh and Andrea will discuss Oncocyte’s innovative diagnostic technologies...

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Mar 24, 2025

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million GraftAssure RUO assay launched July 2024 Signed strategic partner and investor, Bio-Rad Laboratories Fully funded clinical kitted product development with $50+ million in equity raises Advanced science in transplant; achieved Medicare claims expansion IRVINE, Calif., March 24, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to...

Oncocyte Prices $29.1 Million Equity Offering

Feb 10, 2025

Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial Launch Strategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization IRVINE, Calif., Feb. 10, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering (“Registered Direct Offering”) and concurrent private placement (“PIPE...

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Jan 6, 2025

Medicare coverage expanded following study showing that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA) MolDX confirms eligibility for billing under current Local Coverage Determination (LCD) and Z-Code Up to 20% of patients will have detectable DSA within the first five years post kidney transplant, representing greater than 10,000 patients per year in the US.1 From time of onset of dnDSA, 24%...

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Aug 12, 2024

Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure IRVINE, Calif., August 12, 2024 — Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, announced the recent publication of a case series of two kidney transplant patients who were monitored for antibody-mediated rejection (AMR) using its proprietary VitaGraft™ Kidney diagnostic test. Patients were tested before, during...

NEWSROOM

Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Oncocyte Prices $29.1 Million Equity Offering

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Contact Us